Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery

Clinical article

Lars U. Wahlberg M.D., Ph.D. 2 , 5 , Göran Lind M.D. 1 , Per M. Almqvist M.D., Ph.D. 1 , 5 , Philip Kusk Ph.D. 5 , Jens Tornøe Ph.D. 5 , Bengt Juliusson Ph.D. 5 , Michael Söderman M.D., Ph.D. 3 , Eva Selldén M.D., Ph.D. 4 , Åke Seiger M.D., Ph.D. 2 , Maria Eriksdotter-Jönhagen M.D., Ph.D. 2 , and Bengt Linderoth M.D., Ph.D. 1
View More View Less
  • 1 Departments of Neurosurgery,
  • 2 Geriatric Medicine,
  • 3 Neuroradiology, and
  • 4 Anesthesiology, Karolinska University Hospital, Stockholm, Sweden; and
  • 5 NsGene A/S, Ballerup, Denmark
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

The authors describe the first clinical trial with encapsulated cell biodelivery (ECB) implants that deliver nerve growth factor (NGF) to the cholinergic basal forebrain with the intention of halting the degeneration of cholinergic neurons and the associated cognitive decline in patients with Alzheimer disease (AD). The NsG0202 implant (NsGene A/S) consists of an NGF-producing, genetically engineered human cell line encapsulated behind a semipermeable hollow fiber membrane that allows the influx of nutrients and the efflux of NGF. The centimeter-long capsule is attached to an inert polymer tether that is used to guide the capsule to the target via stereotactic techniques and is anchored to the skull at the bur hole.

Methods

Six patients with mild to moderate AD were included in this Phase Ib open-label safety study and were divided into 2 dose cohorts. The first cohort of 3 patients received single implants targeting the basal nucleus of Meynert (Ch4 region) bilaterally (2 implants per patient), and after a safety evaluation, a second cohort of 3 patients received bilateral implants (a total of 4 implants per patient) targeting both the Ch4 region and the vertical limb of the diagonal band of Broca (Ch2 region). Stereotactic implantation of the devices was successfully accomplished in all patients. Despite extensive brain atrophy, all targets could be reached without traversing sulci, the insula, or lateral ventricles.

Results

Postoperative CT scans allowed visualization of the barium-impregnated tethers, and fusion of the scans with stereotactic MR images scan was used to verify the intended positions of the implants. Follow-up MRI at 3 and 12 months postimplantation showed no evidence of inflammation or device displacement. At 12 months, implants were successfully retrieved, and low but persistent NGF secretion was detected in half of the patients.

Conclusions

With refinement, the ECB technology is positioned to become an important therapeutic platform in restorative neurosurgery and, in combination with other therapeutic factors, may be relevant for the treatment of a variety of neurological disorders. Clinical trial registration no.: NCT01163825.

Abbreviations used in this paper:AD = Alzheimer disease; ECB = encapsulated cell biodelivery; NGF = nerve growth factor.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: Lars U. Wahlberg, M.D., Ph.D., NsGene, Inc., 225 Chapman Street, Providence, Rhode Island 02905. email: luw@nsgene.com.

Please include this information when citing this paper: published online June 1, 2012; DOI: 10.3171/2012.2.JNS11714.

  • 1

    Cooper JD, , Salehi A, , Delcroix JD, , Howe CL, , Belichenko PV, & Chua-Couzens J, : Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98:1043910444, 2001

    • Search Google Scholar
    • Export Citation
  • 2

    Eriksdotter-Jönhagen M, , Linderoth B, , Lind G, , Aladellie L, , Almkvist O, & Andreasen N, : Encapsulated cell biodelivery of NGF to the basal forebrain of Alzheimer patients. Dement Geriatr Cogn Disord [in press] 2012

    • Search Google Scholar
    • Export Citation
  • 3

    Eriksdotter Jönhagen M, , Nordberg A, , Amberla K, , Bäckman L, , Ebendal T, & Meyerson B, : Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9:246257, 1998

    • Search Google Scholar
    • Export Citation
  • 4

    Fiandaca MS, , Forsayeth JR, , Dickinson PJ, & Bankiewicz KS: Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5:123127, 2008

    • Search Google Scholar
    • Export Citation
  • 5

    Fjord-Larsen L, , Kusk P, , Emerich DF, , Thanos C, , Torp M, & Bintz B, : Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther [epub ahead of print] 2011

    • Search Google Scholar
    • Export Citation
  • 6

    Fjord-Larsen L, , Kusk P, , Tornøe J, , Juliusson B, , Torp M, & Bjarkam CR, : Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain. Mol Ther 18:21642172, 2010

    • Search Google Scholar
    • Export Citation
  • 7

    Folstein MF, , Folstein SE, & McHugh PR: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189198, 1975

    • Search Google Scholar
    • Export Citation
  • 8

    Hefti F, & Mash DC: Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging 10:7587, 1989

    • Search Google Scholar
    • Export Citation
  • 9

    LeWitt PA, , Rezai AR, , Leehey MA, , Ojemann SG, , Flaherty AW, & Eskandar EN, : AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309319, 2011

    • Search Google Scholar
    • Export Citation
  • 10

    Lindner MD, , Kearns CE, , Winn SR, , Frydel B, & Emerich DF: Effects of intraventricular encapsulated hNGF-secreting fibroblasts in aged rats. Cell Transplant 5:205223, 1996

    • Search Google Scholar
    • Export Citation
  • 11

    Lindvall O, & Wahlberg LU: Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp Neurol 209:8288, 2008

    • Search Google Scholar
    • Export Citation
  • 12

    Mai JK, , Paxinos G, & Voss T: Atlas of the Human Brain ed 3 New York, Academic Press, 2008

  • 13

    McKhann G, , Drachman D, , Folstein M, , Katzman R, , Price D, & Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939944, 1984

    • Search Google Scholar
    • Export Citation
  • 14

    Nagahara AH, , Bernot T, , Moseanko R, , Brignolo L, , Blesch A, & Conner JM, : Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 215:153159, 2009

    • Search Google Scholar
    • Export Citation
  • 15

    Niewiadomska G, , Mietelska-Porowska A, & Mazurkiewicz M: The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res 221:515526, 2011

    • Search Google Scholar
    • Export Citation
  • 16

    Olson L, , Bäckman L, , Ebendal T, , Eriksdotter-Jönhagen M, , Hoffer B, & Humpel C, : Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. J Neurol 242:1 Suppl 1 S12S15, 1994

    • Search Google Scholar
    • Export Citation
  • 17

    Salehi A, , Delcroix JD, & Swaab DF: Alzheimer's disease and NGF signaling. J Neural Transm 111:323345, 2004

  • 18

    Tuszynski MH, , Thal L, , Pay M, , Salmon DP, , U HS, & Bakay R, : A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551555, 2005

    • Search Google Scholar
    • Export Citation
  • 19

    Winn SR, , Hammang JP, , Emerich DF, , Lee A, , Palmiter RD, & Baetge EE: Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc Natl Acad Sci U S A 91:23242328, 1994

    • Search Google Scholar
    • Export Citation
  • 20

    Winn SR, , Lindner MD, , Lee A, , Haggett G, , Francis JM, & Emerich DF: Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences. Exp Neurol 140:126138, 1996

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 894 359 40
Full Text Views 313 45 3
PDF Downloads 209 23 2
EPUB Downloads 0 0 0